Incyte Corporation (INCY) vs Merck & Co., Inc. (MRK)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| INCY | MRK | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - General |
| Size band | LARGE | MEGA |
| Listing | Nasdaq GS | NYSE |
| Country | United States | United States |
| Theme | oncology | oncology |
| Price and returns | ||
| Last close | $113.31 | $140.61 |
| Return · 1 week | +0.05% | −2.10% |
| Return · 1 month | −9.22% | −5.43% |
| Return · 3 months | −12.79% | +6.67% |
| Return · year to date | +11.72% | +33.07% |
| Return · 1 year | +21.73% | +62.34% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −14.55% | −10.39% |
| 52-week high | $132.60 | $156.92 |
| 52-week low | $84.02 | $82.01 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $22.97B | $346.91B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $160.31M | $1.24B |
| Employees | 2,844 | 73,000 |
| Valuation | ||
| Price to earnings · trailing | 14.37× | 115.56× |
| Price to earnings · forward | 12.91× | 15.62× |
| Price to sales | 3.93× | 5.40× |
| Price to book | 3.57× | 8.57× |
| Enterprise value to EBITDA | 9.52× | 13.82× |
| Enterprise value to revenue | 3.18× | 6.00× |
| PEG ratio | 10.82 | 2.59 |
| Earnings per share · trailing | 7.85 | 1.26 |
| Profitability | ||
| Gross margin | 92.62% | 72.97% |
| Operating margin | 41.90% | −0.24% |
| Profit margin | 27.71% | 4.77% |
| Return on equity | 30.67% | 6.96% |
| Return on assets | 16.83% | 11.87% |
| Growth | ||
| Revenue growth | +37.70% | +5.10% |
| Earnings growth | +37.70% | — |
| Balance sheet and payout | ||
| Debt / equity (%) | 0.60 | 128.41 |
| Current ratio | 4.59 | 1.32 |
| Dividend yield | 0.00% | 2.38% |
| Payout ratio | 0.00% | 266.67% |
| Trend and volatility | ||
| RSI · 14 | 43.36 | 42.46 |
| ADX · 14 | 21.26 | 16.51 |
| 50-day average | $121.13 | $146.74 |
| 200-day average | $107.82 | $126.01 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 2.82% | 3.41% |
The full INCY analysis
Everything this table leaves out for Incyte Corporation: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the INCY argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full INCY analysisThe full MRK analysis
Everything this table leaves out for Merck & Co., Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the MRK argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full MRK analysis